How Does Bev + Chemo Perform in'Real World' Ovarian Cancer? How Does Bev + Chemo Perform in'Real World' Ovarian Cancer?
Patients in the nonresearch setting receiving bevacizumab with chemotherapy for ovarian cancer have impressive progression-free survival rates, says Maurie Markman.Medscape Oncology
ConclusionTo optimize targeting and visualization of the surgical field in right pelvic sidewall/paracolic gutter, robotic arms can be placed in a straight line from above the pubic symphysis extending to the left subcostal line and between the midline vertical and midclavicular lines. Robotic tumor debulking should be considered in selected patients with recurrent ovarian cancer who present with oligo-metastatic disease, in the absence of carcinomatosis.
Publication date: November–December 2019Source: Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, SupplementAuthor(s): JM Eom, JS Choi, J Bae, WM Lee, US Jung, H LeeStudy ObjectiveThe aim of this study was to assess the surgical and oncologic outcome of laparoscopic primary cytoreductive surgery on advanced epithelial ovarian cancer in comparison with conventional laparotomy surgery.DesignRetrospective cohort study.SettingUniversity hospital in Korea.Patients or ParticipantsPatients with FIGO stage up to III ovarian cancer undergoing laparoscopic primary cytoreductive surgery from January 2011 to March 20...
CONCLUSION: APMs have the potential to reduce costs of current FFS reimbursement via either a large reduction in imaging or a modest reduction in hospitalizations during treatment of ovarian cancer. PCOP is a reasonable payment structure for oncologists if the additional payments can provide the necessary resources to invest in improved coordination of care. PMID: 31613721 [PubMed - as supplied by publisher]
ConclusionsIntraperitoneal injection of DFP ‐10825 demonstrated effective antitumor activity without systemic severe adverse effects via the selective delivery of RNAi molecules into disseminated tumors in the peritoneal cavity. Our current study indicates that DFP‐10825 could become an alternative option to improve the outcomes of patien ts with peritoneally disseminated gastric cancer.
NICE has approved an ovarian cancer treatment, designed to help maintain the effects of chemotherapy, for use in the cancer drugs fund.
ConclusionLaparoscopic approach to isolated relapse of ovarian cancer is feasible and safe, with fast recovery
Waseem Abbas, Ranga Raju RaoIndian Journal of Cancer 2019 56(4):293-296Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high risk females in comparison to Tamoxifen. Ovarian Function Suppression (OFS) and exemestane became the standard of care, with 30% patients experiencing grade 3 and more side effects. Much higher benefit was seen in high risk group. But there are concerns about inc...
ConclusionsThese results indicate the viability of TIL ACT for refractory ovarian cancer by allowing for the large expansion of anti-tumor TIL in a short time and consistent manner.
This article is protected by copyright. All rights reserved. PMID: 31600840 [PubMed - as supplied by publisher]
ConclusionPARPi as maintenance treatment improved PFS in ovarian cancer and was relatively safer in terms of implications caused by AEs when compared to AIs. This network meta-analysis provides valuable evidence and significant insights into treatment of ovarian cancer.